Regulatory

How Regulatory Status Differs by Compound

The library contains FDA-approved drugs, a discontinued approval, an active Category 2 substance, and unapproved names with withdrawn compounding nominations. Status is per compound.

Therapept EditorialUpdated 12 September 20266 min readReviewed by Therapept Editorial

Bremelanotide is approved; melanotan II is not, despite near-identical mass. Tesamorelin is approved and also WADA-listed. Sermorelin was approved as GEREF and is discontinued. Read the identity record, not the category marketing.

Sources

Drugs@FDA
FDA — Certain bulk drug substances for use in compounding may present significant safety risks

This article is informational. It is not medical, legal or financial advice. Editorial policy · Report a correction